octenidine
Small moleculeexperimental
Octenidine dihydrochloride is a cationic surfactant, with a gemini-surfactant structure, derived from 4-aminopyridine. It is active against Gram-positive and Gram-negative bacteria. Since 1987, it has been used primarily in Europe as an antiseptic prior to medical procedures, including on neonates. — Wikipedia
Clinical trial activity
17 trials · 20 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
12
Phase 3
5
Phase 4
2
Earliest trial started May 1, 2002 (NCT00515151)
Timeline
Indications
Approved for
Studied for
- Bacteremia · Phase 4
- Bacterial Infections · Phase 4
- Burns · Phase 3
- Candidiasis · Phase 2
- Catheterization, Central Venous · Phase 4
- Catheter-Related Infections · Phase 4
- Dry Socket · Phase 2
- Eczema · Phase 2
- General Surgery · Phase 2
- Gingivitis · Phase 3
- Leg Ulcer · Phase 4
- Pressure Ulcer · Phase 3
- Tinea Pedis · Phase 2
- Urinary Bladder, Neurogenic · Phase 2/Phase 3
- Wounds and Injuries · Phase 3
Mechanism of action
- Cell membraneDISRUPTING AGENT
Cell membrane disrupting agent
- Unspecified targetOTHER
Antiseptic
Antiseptic
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(=NCCCCCCCC)cc2)cc1- Mol. weight
- 550.92 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOctenidine dihydrochloride ↗
- ChEMBLCHEMBL61122 ↗
- ChEMBLCHEMBL2106445 ↗
- ChEMBLCHEMBL1199480 ↗
Also known as
- las189962
- n,n'-(1,10-decanediyldi-1-(4h)-pyridinyl-4-ylidene)bis-(1-octamine) dihydrochloride
- n,n'-(1,10-decanediyldi-1(4h)-pyridinyl-4-ylidene)-bis-(1-octanamine) dihydrochloride
- n,n'-(1,10-decanediyldi-1(4h)-pyridinyl-4-ylidene)-bis-(1-octanamine) dihydrochloride
- octeniderm
- octenidine
- octenidine
- octenidine
- octenidine
- octenidine
- octenidine
- octenidine
- octenidine
- octenidine chloride
- octenidine dihydrochloride
- octenidine dihydrochloride
- octenidine hcl
- octenidine hcl
- octenidine hydrochloride
- octenidine hydrochloride
- octenidine hydrochloride
- octenisept
- octenisept
- win 41464-2
- win-414642
- win-414642
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06522438 | N/A | Oct 31, 2024 | QMUL, University of London |
| NCT07173725 | N/A | Mar 8, 2023 | Bezmialem University |
| NCT04172363 | Phase 3 | Nov 22, 2019 | RWTH Aachen University |
| NCT03322124 | Phase 3 | Jan 22, 2018 | Schülke & Mayr GmbH, Technical University of Dresden |
| NCT03378401 | Phase 3 | Jan 11, 2018 | Schülke & Mayr GmbH, University of Applied Sciences Würzburg-Schweinfurt |
| NCT03224299 | Phase 2 | Jun 21, 2017 | Becton Dickinson |
| NCT03229759 | Phase 2 | Jun 21, 2017 | Becton Dickinson, Bio-Science Laboratories |
| NCT03140254 | Phase 2 | Sep 1, 2016 | Becton Dickinson, CareFusion |
| NCT02697162 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2016 | GuardianMed j.d.o.o. Research and development in medicine, University of Zagreb |
| NCT04091399 | Phase 2 | Sep 11, 2015 | Contipro Pharma a.s., University Hospital Hradec Kralove |
| NCT02138552 | Phase 2 | Oct 1, 2013 | Schülke & Mayr GmbH |
| NCT01657292 | Phase 3 | Aug 1, 2012 | Birken AG, Humboldt University |
| NCT01434914 | Phase 4 | Oct 1, 2011 | Schülke & Mayr GmbH, University of Hamburg |
| NCT01096472 | Phase 2 | Feb 1, 2010 | Almirall |
| NCT01102387 | Phase 2 | Feb 1, 2010 | Almirall |
| NCT01020994 | Phase 2 | Nov 1, 2009 | Almirall |
| NCT00515151 | Phase 4 | May 1, 2002 | University of Bern, University of Freiburg |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (20)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Schülke & Mayr GmbH | For profit | 4 | 4 | 3 | 2011 |
| Almirall | For profit | 3 | 3 | 1 | 2009 |
| Becton Dickinson | For profit | 3 | 2 | 1 | 2016 |
| Bezmialem University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Bio-Science Laboratories | For profit | 1 | 0 | 1 | 2017 |
| Birken AG | For profit | 1 | 1 | 1 | 2012 |
| CareFusion | For profit | 1 | 1 | 1 | 2016 |
| Contipro Pharma a.s. | For profit | 1 | 1 | 1 | 2015 |
| GuardianMed j.d.o.o. Research and development in medicine | For profit | 1 | 0 | 1 | 2016 |
| Humboldt University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| QMUL | Academic/Hospital | 1 | 0 | 1 | 2024 |
| RWTH Aachen University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Technical University of Dresden | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University Hospital Hradec Kralove | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Applied Sciences Würzburg-Schweinfurt | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Bern | Academic/Hospital | 1 | 0 | 1 | 2002 |
| University of Freiburg | Academic/Hospital | 1 | 1 | 1 | 2002 |
| University of Hamburg | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Zagreb | Academic/Hospital | 1 | 1 | 1 | 2016 |
20 organizations
Page 1 / 1